Related Experiment Video
Updated: Feb 6, 2026
07:06
Isolation and Characterization of Mesenchymal Stromal Cells from Human Umbilical Cord and Fetal Placenta
Published on: April 3, 2017
48.9K
Mesenchymal Stem/Stromal Cell-Based Therapy for Heart Failure - What Is the Best Source?
Kazuya Kobayashi1, Ken Suzuki1
1William Harvey Research Institute, Barts and The London School of Medicine, Queen Mary University of London.
Summary
Mesenchymal stem/stromal cells (MSCs) show promise for heart failure (HF) treatment. This review compares MSCs from adult, perinatal, and pluripotent sources, evaluating their pros and cons for HF therapy.
Area of Science:
- Regenerative Medicine
- Cardiovascular Research
- Cell Therapy
Background:
- Heart failure (HF) is a significant clinical challenge.
- Stem/progenitor cell transplantation is an emerging therapeutic strategy for HF.
- Mesenchymal stem/stromal cells (MSCs) are a leading candidate due to their reparative and immunomodulatory properties.
Purpose of the Study:
- To review and compare different sources of MSCs for HF treatment.
- To highlight the advantages and disadvantages of adult, perinatal, and pluripotent stem cell-derived MSCs.
- To provide insights for selecting optimal MSC sources for HF therapy.
Main Methods:
- Comprehensive review of preclinical and clinical studies on MSCs for HF.
- Analysis of MSCs derived from adult tissues (bone marrow, adipose).
- Evaluation of MSCs from perinatal tissues (umbilical cord, amnion).
- Assessment of MSCs from pluripotent stem cells (iPSCs, ESCs).
Main Results:
- Adult MSCs are well-studied, but therapeutic effects in HF are debated.
- Perinatal MSCs offer non-invasive sourcing and mass production potential.
- Pluripotent stem cell-derived MSCs allow for large-scale, consistent production but carry tumorigenicity risks.
- Safety and feasibility of MSCs in HF trials are generally suggested, but efficacy varies.
Conclusions:
- Each MSC source presents unique benefits and drawbacks for HF treatment.
- Perinatal and pluripotent stem cell-derived MSCs show potential for scalability.
- Further research is needed to optimize MSC selection and application for effective HF therapy.
Related Concept Videos
01:22Heart Failure VI: Adjunct Therapies
348
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
348
01:19Mesenchymal Stem Cells
5.6K
Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their...
5.6K
01:29Heart Failure II: Pathophysiology
964
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
964
01:17Pathophysiology of Heart Failure
3.8K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.8K
01:27Heart Failure I: Introduction
903
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
903
01:27Source And Potency Of Stem Cells
6.3K
Stem cells are undifferentiated cells with extensive self-renewal properties that help them maintain their population during the fetal and adult stages of life. They can specialize in all cell types of the human body. However, their differential potential may vary and can be classified into five types. Stem cells can be (1) Totipotent, (2) Pluripotent, (3) Multipotent, (4) Oligopotent, and (5) Unipotent. Each stem cell has a specific origin; the fertilized egg or zygote is a totipotent cell and...
6.3K